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Abstract
Background: Colorectal cancer (CRC) is the second leading cause of cancer deaths despite the fact that detection of this
cancer in early stages results in over 90% survival rate. Currently less than 45% of at-risk individuals in the US are screened
regularly, exposing a need for better screening tests. We performed two case-control studies to validate a blood-based test
that identifies methylated DNA in plasma from all stages of CRC.
Methodology/Principal Findings: Using a PCR assay for analysis of Septin 9 (SEPT9) hypermethylation in DNA extracted
from plasma, clinical performance was optimized on 354 samples (252 CRC, 102 controls) and validated in a blinded,
independent study of 309 samples (126 CRC, 183 controls). 168 polyps and 411 additional disease controls were also
evaluated. Based on the training study SEPT9-based classification detected 120/252 CRCs (48%) and 7/102 controls (7%). In
the test study 73/126 CRCs (58%) and 18/183 control samples (10%) were positive for SEPT9 validating the training set
results. Inclusion of an additional measurement replicate increased the sensitivity of the assay in the testing set to 72% (90/
125 CRCs detected) while maintaining 90% specificity (19/183 for controls). Positive rates for plasmas from the other cancers
(11/96) and non-cancerous conditions (41/315) were low. The rate of polyp detection (.1 cm) was ,20%.
Conclusions/Significance: Analysis of SEPT9 DNA methylation in plasma represents a straightforward, minimally invasive
method to detect all stages of CRC with potential to satisfy unmet needs for increased compliance in the screening
population. Further clinical testing is warranted.
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Introduction
Colorectal cancer (CRC) is one of the most common neoplasms
found in men and women in the United States. The American
Cancer Society had estimated that 154,000 new cases of CRC
would occur in 2007, resulting in more than 52,000 deaths.
Screening programs for the identification of early stage CRC and
pre-neoplastic conditions can significantly improve disease out-
come because of the treatment benefit of early detection [1].
Current non-invasive screening procedures are not very effective,
as they require patient compliance to self-collect stool sample
analyzed annually for the presence of occult blood (FOBT) [2]. To
date, improvements in feces-based tests by making them more
sensitive and more user friendly have not increased compliance in
CRC screening. Invasive screening tests such as colonoscopy or
sigmoidoscopy, although more effective, require extensive bowel
preparation, invasion of privacy, and sedation, and do not
overcome current compliance issues in CRC screening. There is
growing expectation that the new generation of screening tests
based on molecular biomarkers present in blood should improve
patient compliance in CRC screening as evidenced by the success
of other screening programs such as cholesterol/lipids and prostate
specific antigen (PSA) [5–7].
Determination of epigenetic events is a strong candidate for
early detection of disease since regulation of gene expression by
aberrant DNA methylation is a well-characterized event in tumor
biology [8,9], and is extensively described for CRC [10–12].
Increased levels of free-circulating methylated DNA in the blood
of cancer patients compared to healthy controls have been
reported [13,14]. Several laboratories also reported promising
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DNA methylation-based marker candidates for detection of CRC
[15–19]. Translating such marker candidates into clinically
validated and commercially viable tests has been exceedingly slow
and inadequate. To facilitate improvements in biomarker
translation medicine Pepe et al. proposed a systematic process for
biomarker validation for early detection of cancer with 5 distinct
phases, each phase providing increased level of evidence of marker
validation [20]. In an initial study we presented the first level of
evidence that SEPT9, a DNA methylation-based biomarker,
effectively discriminates CRC from normal specimens [21]. The
Septin 9 gene belongs to a class of GTPases involved in numerous
cellular process [22].The gene has been shown to have multiple
alternatively spliced transcripts encoding at least 5 characterized
polypeptides designated v1–v5 [23], some of which have been
associated with cancer. The ratio of v4 and v4* expression,
identical proteins encoded by different transcripts, has been shown
to be altered in ovarian cancer with v4 being the predominant
form expressed in normal cells and v4* expressed in tumors [24].
Recent studies of the v1 isoform suggest that over-expression of
this polypeptide may promote tumor progression in mammary
tissue [25]. Our previous work describing aberrant methylation in
the promoter region of the v2 transcript indicates that methylation
in this region is associated with colorectal cancer [21]. Moving
forward in the process proposed by Pepe et al, in this report we
provide the second level of evidence by presenting results from
validation of clinical assay for SEPT9 in two large independent
plasma sets demonstrating the potential of this marker for early
detection of CRC. Increasing the number of assay replicates tested
resulted in high sensitivity for CRC with excellent specificity in
healthy controls. Specificity was further evaluated in a number of
disease controls. Finally, the SEPT9 methylation of pre-malignant
lesions is reported.
Methods
Patients
700 patient samples collected at 9 sites were measured in the
training study. It included patients with all stages of colorectal
cancer, individuals without diseases of the colon as verified by
colonoscopy, additional disease controls and a number of patients
with adenomatous polyps (Table 1). A subset of 354 samples (only
CRCs and normals with complete SEPT9 measurement) was used
to generate the training set algorithm. The test study consisted of
547 patient samples (a subset of 309 CRCs and normals with
complete SEPT9 measurement was used as a test set) collected at
14 sites and included similar clinical categories of samples as used
in the training study. Additional disease controls were collected
from individuals with non-colorectal cancers and various non-
cancerous diseases for additional specificity testing. Not all of those
subjects were verified with colonoscopy as CRC-and/or adenoma-
free. Written informed consent was obtained from all study
participants adhering to the local ethical guidelines.
All cancer patients and healthy controls enrolled in both studies
were at least 40 years old with a preference for patients 50 and
older and derived predominantly from the same clinics. All
subjects participating had neither a personal history of HIV, HBV
or HCV or previous history of cancer with the exception of basal
cell carcinoma nor symptoms of severe acute nor exacerbated
chronic disease.
Blood from all subjects has been drawn either before or more
than 2 days and up to 6 months after colonoscopy and prior to
starting any cancer specific treatment. Cancer diagnosis was
confirmed histologically from the surgical specimen and only
adenocarcinomas were included in this study.
Sample processing workflow
A 3-part workflow was developed for the SEPT9 test (Figure 1).
DNA Extraction: Free-floating circulating DNA was extracted
from plasma using the Total Nucleic Acid Large Volume DNA
extraction kit (Roche Applied Science, Indianapolis, IN) and
Roche MagNaPure device. Eight or 16 mL of plasma was
distributed in MagNaPure wells (1 mL per well), extracted
following the kit protocol, and DNA was eluted in 100 mL
aliquots. Eluates from each patient were pooled and concentrated
to a final volume of 100 mL using Microcon YM-30 filters
(Millipore). A 5 mL aliquot of each sample was retained to measure
total genomic DNA using the real-time PCR assay (CFF1)
described in Supplementary Table S1. Bisulfite Treatment:
Concentrated DNA samples were bisulfite treated using methods
to achieve maximal conversion and DNA recovery [35]. A 5 mL
aliquot of each sample was retained to measure total bisulfite
treated DNA using the real-time PCR assay (HB14) described in
Supplementary Table S1. Real Time PCR Analysis: The SEPT9
real time PCR assay is designed surrounding the transcription start
site of the v2 transcript. The real time assay sequences, cycling
conditions and quality control process are described in the
Supplementary Text S1 and Supplementary Figure S1. For total
genomic and total bisulfite converted DNA measurements, PCR
was performed on a 1:10 dilution (in elution buffer) of the
respective materials. For SEPT9 measurements on samples,
reactions were performed on 10–12.5 mL of undiluted DNA
depending on experiment. PCR was performed using the Roche
LightCycler 2.0 device with the FastStart DNA Master HybProbe
master mix (Roche Applied Science). Each PCR run included a
DNA Standard curve prepared using bisulfite treated CpGenome
Universal Methylated DNA (Millipore (Chemicon), Billerica, MA)
at concentrations between 50 pg/rxn–20 ng/rxn. Each run also
included a no template control which was left uncapped
throughout the process to control for contamination, and 3 no-
template controls which were used to establish the baseline of the
PCR reaction. Samples were run as single capillaries on each PCR
run, and replicates were performed in separate PCR runs.
Amplification curves for each reaction were manually verified by
2 independent reviewers.
Data analysis
Patient samples for training and test study were grouped according
to diagnosis and gender and randomly assigned to DNA extraction
batches. In addition test study samples were blinded prior to
processing in the laboratory and data analysis. Quantitative real-time
PCR analysis of plasma samples was performed as described earlier
and replicate measurements were averaged.[21] Chi square test was
used to compare detection rates between different locations of tumor,
age, tumor stage and gender. Wilcoxon-Mann-Whitney test and
Kruskall-Wallis test were used to quantitatively compare methylated
Septin 9 DNA concentrations between different locations of tumor,
age, tumor stage and gender. Confidence intervals for proportions of
detected samples were set at 95% and based on binomial
distributions. All P values are two-sided.
Results
The objective of this investigation was to validate the use of
SEPT9 hypermethylation as a biomarker for colorectal cancer by
determining the optimal classifier using a set of samples (training
study) and confirming the selected classifier in an independent
sample set (test study). Each plasma sample was processed using a
three-step workflow outlined in Figure 1. The workflow process
was carefully monitored with addition of positive and negative
Colorectal Cancer Detection
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controls at each process step and individual samples were accepted
for final analysis after passing quality control specifications (see
Supplementary Text S1).
Training Study
The demographic and clinical parameters of the subjects
included in the training study are outlined in Table 1. Three
hundred fifty-four colorectal cancer and normal control samples
were included in the primary data analysis. The training study
data was analyzed qualitatively, where a SEPT9 reaction was
called positive if a distinct PCR curve was detected. Each plasma
sample was measured in three independent PCR reactions and
based on analysis of clinical performance, patient samples were
classified as positive if two out of three PCR replicates were called
positive. Based on this qualitative algorithm we measured a
sensitivity of 48% for colorectal cancer and a specificity of 93% for
non-colorectal disease colonoscopy-verified samples. Alternatively,
we determined optimal thresholds based on quantitative analysis
of the SEPT9 marker. These quantitative algorithms did not
improve overall marker performance (see Supplementary Table
S2). Using the qualitative analysis, we analyzed correlations
between detection of colorectal cancer and different clinical
parameters. There was no significant difference in detection rate
by location of tumor, age or gender. Early stage colorectal cancers
were detected at slightly lower rates (43%) than later stage cancers
(55%) but the difference was not significant. There was also no
significant quantitative difference between amounts of methylated
SEPT9 DNA between different stages (Figure 2A). The SEPT9
marker also detected 22% of polyps larger than 1 cm.
Test Study
To confirm the clinical performance of the SEPT9 training
algorithm we collected plasma samples from an independent
patient set (test set – Table 1). Compared to the training set the test
set contained significantly fewer early stage cancers and cancer
patients were slightly older. Using the SEPT9 threshold deter-
mined in the training study we were able to confirm marker
performance in the test set of 309 colorectal cancer patients and
healthy controls with sensitivity of 58% and specificity of 90%
(Table 2).
There was no significant difference in detection rate by
location of tumor, age or gender. Early stage colorectal cancers
Table 1. Patient characteristics of training and test studies.
Diagnosis Group Description Total 4 Gender Age Location
1
Male Female ,50 50–59 60–69 $70 Median5 Distal Proximal
Training Set
Colorectal Cancer Stage I 63 30 33 9 16 18 20 61 41 21
Stage II 83 46 37 10 28 28 17 61 50 33
Stage III 59 37 22 2 22 26 9 60 47 10
Stage IV 29 16 13 5 8 10 6 60 21 6
Stage NA 19 15 4 2 5 8 4 64 14 5
Adenomas/Polyps ,10 mm 53 27 26 10 13 16 14 61 34 19
$10 mm 65 37 28 38 25 2 0 47 62 3
Healthy/Normal Colon 102 36 66 19 34 27 22 59
Non-colorectal Cancer2 60 34 25 11 18 20 11 61
Non-cancerous Disease 3 167 63 103 71 39 38 19 52
Total 700 341 357 177 208 193 122 58 269 97
Test Set
Colorectal Cancer Stage I 22 15 7 0 4 6 10 69 11 1
Stage II 37 23 14 1 8 13 11 67 11 8
Stage III 54 27 27 2 10 17 20 67 26 7
Stage IV 11 8 3 0 4 4 3 63 4 0
Stage NA 3 3 0 1 1 0 0 49 1 0
Adenomas/Polyps ,10 mm 34 21 13 0 4 19 11 68 0 0
$10 mm 17 14 3 1 4 9 3 66 0 0
Healthy/Normal Colon 184 76 106 34 72 42 33 56
Non-colorectal Cancer 36 22 14 4 5 14 8 65
Non-cancerous Disease 149 57 92 14 29 56 41 66
Total 547 266 279 57 141 180 140 63 53 16
1Colorectal lesions are divided regarding their location into ‘Distal’: descending, sigmoid, left flexure, rectum and ‘Proximal’: cecum, ascending, right flexure, transverse.
2Non-colorectal Cancer include bladder, breast, liver, lung, prostate and pancreatic cancers.
3Non-cancerous Diseases include gastritis, hypertension, type II diabetes, liver disease, rheumatoid and non- rheumatoid arthritis, cholycystitis, cystitis, chronic heart
disease, esophagitis, IBD, pancreatitis, chronic renal failure, respiratory infection.
4Total sample numbers can be higher than the sum of all subgroups when sample annotations are missing, for some patient samples SEPT9 methylation measurement
was incomplete.
5Median patient age at time of sample collection in years.
doi:10.1371/journal.pone.0003759.t001
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were detected at lower rates (36%) than later stage cancers (73%)
but the difference in detection rate was not significant. However,
there was a significant quantitative difference between amounts
of methylated SEPT9 DNA between different stages (P,0.002;
Figure 2B). Large polyps (.1 cm) were detected at a rate of
18%.
Figure 1. Sample processing workflow. The diagram depicts the major sample processing and laboratory workflow steps. It shows where
process control samples are introduced into the workflow and what assays were used to measure output of each process step. Grey boxes indicate
test set specific workflow steps.
doi:10.1371/journal.pone.0003759.g001
Figure 2. Concentrations of methylated SEPT9 DNA in plasma. Box-percentile plots of training set methylated SEPT9 DNA concentrations in
plasma are shown for colonoscopy-verified normal patients (Normal) and patients with colorectal cancer (CRC). Median DNA concentrations are red
horizontal lines; 25th and 75th percentiles are blue horizontal lines. The width of the box-percentile plot at any given height is proportional to the
percent of observations that are more extreme in the direction leading away from the median. Individual measurement values are plotted as grey
circles. B) Box-percentile plots of testing set methylated SEPT9 DNA concentrations in plasma.
doi:10.1371/journal.pone.0003759.g002
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Improved process yields better SEPT9 performance
During our routine quality control we observed sporadic
inhibition of the PCR reaction (see Supplementary Figure S2).
Therefore we analyzed an additional SEPT9 replicate using 10
fold-diluted samples available from the original total bis-DNA
measurements. The correlation plot of the standard SEPT9
measurement (mean of three standard replicates) and a single
measurement of the diluted sample is shown in Figure 3.
There are three groups of samples: group1 in which SEPT9
amplification was identical in standard and diluted samples, group
2 in which only standard concentration samples amplified and
group 3 in which only the diluted samples amplified. Group 2
consists of samples for which no PCR inhibition was observed, but
contained levels of tumor DNA insufficient for amplification of
SEPT9 after dilution. Group 3 samples displayed PCR inhibition
in standard concentration, but when diluted, showed SEPT9
amplification. We incorporated the result of this additional
measurement into a new algorithm in which a patient sample is
classified positive if either two out of three standard PCR replicates
are positive (training set algorithm) OR the measurement of the
diluted sample is positive. Reanalysis of the test set results using
this algorithm dramatically improved the performance of the
SEPT9 assay (Table 2).
Overall colorectal cancer detection reached 72% while
maintaining very high specificity of 90%. Especially impressive
were improvements in detection of early stage cancer (Stage I/II –
sensitivity 62%) confirming the potential value of SEPT9 as an
early detection biomarker for colorectal cancer.
Non colorectal cancer (NCC) and non cancerous diseases
(NCD) sample analysis
We also collected and analyzed a subset of plasma samples from
patients diagnosed with non-colorectal cancers (NCC) including
bladder, breast, lung, liver, pancreas and prostate cancers as well
as non-cancerous disease that may have confounding effects on the
SEPT9 marker performance. As shown in Table 3, SEPT9 is
exceptionally specific regarding colorectal cancer when compared
to detecting NCCs: only a few plasma samples from liver cancer (2
out of 8 samples), lung cancer (4 out of 13) and bladder cancer (4
out of 19) patients were positive for the marker. The low
percentage of SEPT9 present in multiple non-cancerous disease
groups, e.g. chronic renal failure, gastritis, and chronic respiratory
infections (see Table 3) points to its high specificity for colorectal
cancer malignancy.
Discussion
In this report we determined performance of a real-time PCR
assay for methylated SEPT9 DNA first in a training study and
then in a blinded independent testing study. Overall sensitivity for
colorectal cancers was comparable in both studies as identified
using the original training algorithm. Sensitivity increased to 72%
with an additional SEPT9 replicate of the 10-fold diluted plasma
sample. The marker was shown to be sensitive for early-stage
colorectal cancers identifying 62% of Stage I/II CRCs. There was
a trend for early stage colorectal cancers to be detected at slightly
lower rates than later stage cancers in both the training and testing
study, but the differences were not significant due to insufficient
number of samples for each individual stage of cancer. Sensitivity
of CRC detection was completely independent of tumor location
Table 2. Septin9 marker performance – training and testing studies.
Patient Group Septin9 Training Septin9 Testing Septin9 Testing Re-Analyzed
2 positive out of 3 2 positive out of 3 2 positive out of 3 OR positive diluted
% [95% CI] Pos/Total % [95% CI] Pos/Total % [95% CI] Pos/Total
Healthy 7 [3,14] 7/102 10 [6,15] 18/183 10 [6,16] 19/183
CRC All 48 [41,54] 120/252 58 [49,67] 73/126 72 [63,80] 90/125
CRC I–III 47 [40,54] 95/204 56 [47,66] 63/112 70 [61,79] 78/111
CRC I 43 [30,56] 27/63 36 [17,59] 8/22 50 [28,72] 11/22
CRC II 44 [33,55] 36/82 56 [38,72] 20/36 69 [52,84] 25/36
CRC III 54 [41,67] 32/59 65 [51,77] 35/54 79 [66,89] 42/53
CRC IV 55 [36,74] 16/29 73 [39,94] 8/11 91 [59,100] 10/11
Polyp$10 mm 22 [13,34] 14/64 18 [4,43] 3/17 18 [4,43] 3/17
Polyp,10 mm 9 [3,21] 5/53 9 [2,24] 3/34 9 [2,24] 3/34
doi:10.1371/journal.pone.0003759.t002
Figure 3. Correlation between standard and diluted SEPT9
measurement in testing set. X-axis – concentration of SEPT9 in
standard test set samples (mean of three standard replicates) Y-axis –
concentration of SEPT9 in 1:10 diluted test set samples (single
replicate). mDNA – methylated DNA. Group 1 – samples with the same
SEPT9 amplification in standard and diluted concentration, group 2 –
samples with SEPT9 amplification only in standard concentration, group
3 – samples with SEPT9 amplification only in diluted concentration.
Green triangles – healthy colon, red circles – colorectal cancer, black
squares – polyps.
doi:10.1371/journal.pone.0003759.g003
Colorectal Cancer Detection
PLoS ONE | www.plosone.org 5 November 2008 | Volume 3 | Issue 11 | e3759
in colon. This may be a general feature of methylation biomarkers
since Chen et al. noted a similar lack of correlation to stage or
location in a recent study in stool of patients with colorectal cancer
[26]. Other fecal tests such as FOBT and iFOBT have been shown
to have a decreased sensitivity for both proximal colorectal cancers
and early stage cancers [27]. Finally, our results indicate that the
biomarker is also highly specific (90–93%) in healthy individuals.
We developed a very sensitive PCR assay to detect methylated
v2 promoter of SEPT9 in plasma samples. Effective validation of
such a test depends as much on quality of the biomarker as on the
quality and consistency of the workflow steps, including the final
marker measurement. We controlled our workflow at each step;
assessing variability of DNA extraction, bisulfite conversion and
PCR amplification and because of such quality control we were
able to identify sporadic PCR inhibition in the test set.
Overcoming this issue by diluting the PCR reaction 10-fold and
combining this measurement with the undiluted measurement
yielded the true performance of the SEPT9 marker. The use of
four assay replicates (3 standard replicates and 1 diluted) allows
alternative analysis focusing either on sensitivity or specificity of
the marker assay. By requiring SEPT9 to be present in all standard
replicates or one diluted replicate before a sample is classified
positive, the test achieves a very high specificity (97%) and still
retains substantial sensitivity (65%). When only 1 of 4 replicates
(either one standard or one diluted) is required to be positive for a
positive call (high sensitivity mode) the sensitivity increases to 77%
whereas specificity is still respectable at 75% [see Supplementary
Table S3].
The control patient groups in our studies included a primary set
of individuals without diseases of the colon as verified by
colonoscopy but some with conditions likely to be present within
the CRC screening population. We made every effort to avoid
patient selection bias in the study by requiring controls to be in the
same age range as CRCs and to be derived predominantly from
the same clinics as our CRC patients. Despite these efforts some
biases remained: the majority of CRC patients in training and test
set are male (57% and 60% respectively), and test set patients are
slightly older than training set patients. However, since we found
that detection of CRC is independent of age and gender the
reported SEPT9 performance should be unaffected. Our primary
analysis compares the performance of the marker in plasma from
patients with colorectal cancer vs. the subjects without colorectal
disease. We performed additional analyses using non-cancerous
disease controls and plasma from cancers other than colorectal to
identify potential specificity issues. The numbers of patients with
these conditions are not weighted according to their prevalence,
and therefore true specificity regarding these diseases cannot be
determined for the target screening population. Since the observed
positive rate of the marker is very low in the control samples, we
believe that the SEPT9 marker will perform well in future
prospective clinical studies when measured in CRC screening
population.
The SEPT9 test aims at detecting asymptomatic colorectal
cancer cases. We also obtained preliminary data on polyp
detection with the SEPT9 assay that indicate some pre-malignant
changes are identified with our test. The ultimate CRC screening
test should also target adenomas that will advance to cancer and
that could be removed during follow up colonoscopy. While today
we do not yet fully understand the natural history of adenomas,
and cannot predict which ones would progress to cancer, it is
tempting to speculate that epigenetic markers, like SEPT9, may
help with such polyp stratification.
The Septin 9 gene, also called MSF, encodes a mammalian
septin protein involved in many cellular processes. Disruption of
the action of Septin 9 results in incomplete cell division [28]. Septin 9
and other proteins have been shown to be fusion partners of the
proto-oncogene MLL suggesting a role in tumorigenesis [29,30].
Septin 9 has also been shown to be in a frequently deleted region in
breast and ovarian cancers in loss of heterozygosity (LOH) studies,
a finding that further implicates the gene as a possible tumor
suppressor [31]. Burrows et al. reported an in depth study of
expression of the multiple isoforms of the Septin 9 gene in ovarian
cancer and showed tissue specific expression of various transcripts
[32]. Expression of the v4 transcript of Septin 9 was shown to be
absent or diminished in several cell lines and could be reactivated
by treatment with 5-azacytidine, providing initial evidence of
potential regulation of the gene by DNA methylation. Additional
evidence of methylation control of the v2 transcript was provided
in a recent quantitative analysis in tissues and plasma from
colorectal cancer patients [21]. Furthermore a recent study by
Bennett et al. indicates that methylation of the Septin 9 gene also
occurs in head and neck cancers, however the region of the
methylation event is not described [33]. Over-expression of Septin 9
isoforms has also been demonstrated in a number of tumor tissues.
A previous study of over 7000 normal and tumor tissues indicates
that tissue specific expression of Septin 9 transcripts occurs in a
Table 3. Septin9 performance in NCC and NCD samples.
Patient Group Positive/Total
Non Colorectal Cancer 11/96
Bladder 4/19
Breast 0/30
Liver 2/8
Lung 4/13
Pancreas 0/5
Prostate 1/19
Stomach 0/2
Non Cancerous Disease 41/315
Inflammatory Bowel Disease 2/20
Esophagitis 1/28
Gastritis 7/24
Diverticulitis 0/5
Diverticulosis 0/9
Appendicitis 1/8
Pancreatitis 1/20
Cholycystitis 3/21
Cystitis 1/13
Liver Disease 1/14
Collagenosis 0/5
Diabetes Type II 0/14
Lupus 2/14
Allergy 0/5
Arthritis non-rheumatoid 2/28
Arthritis rheumatoid 4/25
Heart Disease Chronic 2/17
Pyelonephritis 3/8
Renal Failure Chronic 5/13
Respiratory Infection 6/24
doi:10.1371/journal.pone.0003759.t003
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wide variety of cancers [23] The authors speculate that the gene is
likely a type II cancer gene where changes in RNA transcript
processing control regulation of different protein products, and the
levels of these altered protein isoforms may provide answers to the
gene’s role in malignancy. This hypothesis is consistent with recent
studies that show Septin 9 isoform over-expression is associated
with an oncogenic phenotype [24,25] and evidence that Septin 9
v1 over-expression is associated with tumor resistance to drugs that
disrupt microtubule formation [34].
So far current CRC screening strategies failed to improve
patient compliance and to lower mortality of colorectal cancer.
Most experts anticipate an improved patient CRC screening
compliance with blood-based test, as was the case for prostate
cancer screening with PSA or in heart disease with cholesterol/
lipids testing. This report describes the first validation of a plasma-
based DNA methylation test performed in two large well-
controlled case-control studies confirming clinical potential of
SEPT9 biomarker for CRC screening application. We believe that
such an easily administered blood-based test for early detection of
colorectal cancer followed by colonoscopy for positive individuals
has the potential to be a very effective tool for reducing mortality
from this disease. The SEPT9 marker assay warrants further
evaluation as a test for early CRC detection and prospective
studies are planned to determine clinical performance in screening
guideline-eligible screening populations.
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